Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz is investigating Alnylam Pharmaceuticals for potential federal securities law violations. On July 30, 2026, Alnylam lowered its full-year 2026 TTR product sales guidance by approximately $200 million due to slower-than-expected growth in the ATTR-CM market after initial pent-up demand was satisfied. The announcement triggered a sharp 28.31% stock price decline, causing investor losses.